Healthcare entity
Wall Street Zen is the most frequent co-covered peer, appearing in 6 of the 8 tracked stories. Negative sentiment reaches 0% here, compared with 26% across the 388-story beat baseline for the same window. Each story carries 2.3 original sources on average, compared with 3.5 for the broader beat in this window.
Last mentioned: 19h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Wall Street Zen is the most frequent co-covered peer, appearing in 6 of the 8 tracked stories. Negative sentiment reaches 0% here, compared with 26% across the 388-story beat baseline for the same window. Each story carries 2.3 original sources on average, compared with 3.5 for the broader beat in this window. At 5, the average consequence score sits below the same-window beat average of 6. That works out to roughly 1.3 stories per week across a 43-day span. The busiest single day carried 2. market-trends accounts for 4 of the 8 tracked stories, while 2 other categories carry the remainder. We currently track 8 Healthcare stories that mention Weiss Ratings, published between July 5, 2026 and August 16, 2026.
Computed from the 8 stories linked to this entity, with beat comparisons drawn from all 388 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Weiss Ratings. Shared-story counts are live from our verified record — not editorial picks.
Q2 2026 Earnings Release
Company reported EPS of ($0.19), missing consensus by $0.03.
Ladenburg Thalmann Upgrade
Ladenburg Thalmann upgraded CRVS to ‘strong-buy’.
Weiss Ratings Upgrade
Weiss Ratings upgraded Corvus from ‘sell (e+)’ to ‘sell (d-)’.
Director Insider Purchase
Director David Scott Moore acquired 21,700 shares at $11.53 per share, totaling $250,201.
Wall Street Zen Downgrade
Wall Street Zen downgraded CRVS from ‘hold’ to ‘sell’.
Goldman Sachs Initiates Coverage
Goldman Sachs issued a ‘buy’ rating and a $40.00 target price for Corvus Pharmaceuticals.
Lantern Pharma's quarterly EPS miss of $0.19 highlights the cash-intensive nature of AI-powered oncology drug discovery. The clinical-stage company has no product revenue, and its stock trades well below moving averages. Healthcare executives should monitor its platform and funding runway rather than quarterly losses.
For healthcare and medical device stakeholders, Apyx Medical's Q1 revenue of $12.49 million beat consensus by $1.96 million, yet the stock fell 1.8% to $4.38. The decline on 60% below-average volume suggests limited conviction, while analysts maintain a moderate buy rating and $6.50 target. The company's strong liquidity ratios contrast with its negative net margin and return on equity.
Ensysce Biosciences short interest soared 619.9% to 364,278 shares as its stock trades at $0.30, while Focus Universal posted just $0.05M in quarterly revenue. The data highlights severe financial fragility across two small healthcare and device innovators.
Corvus Pharmaceuticals missed Q2 EPS by $0.03, highlighting the financial fragility of early-stage oncology R&D. With no near-term data readouts, the miss draws attention to cash burn and the critical need for clinical progress to justify its $1.17B valuation.
Source: dailypolitical.com · tickerreport.com
Teva Pharmaceutical's FY2026 EPS guidance fell short of the $2.17 consensus, while revenue projections of $16.5-$16.9B matched expectations. For healthcare leaders, the miss underscores ongoing generic drug pricing pressures and the importance of a diversified pipeline.
Wall Street Zen downgraded vaccine maker Novavax to sell, raising alarms in the healthcare sector. The stock traded at $7.41, far below its $13 consensus target, with a negative P/E of -12.78.
Analyst downgrades reflect growing fears that GLP-1 weight loss drugs could erode the sleep apnea device market, even as ResMed’s financials stay solid. The contrast between a $225 low target and $321 high target underscores sector uncertainty.
A major Shuttle Pharmaceuticals shareholder just poured $110,694 into the beaten-down stock, buying 32,591 shares at near all-time lows. For healthcare investors, this insider vote of confidence in a radiation oncology developer could signal upcoming clinical catalysts or a potential turnaround.
Weiss Ratings is linked from 8 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
